The international industrial conglomerate Honeywell (Nasdaq: HON) has opened a facility in Baton Rouge, Louisiana, to produce its new Solstice Air (HFO-1234ze(E) cGMP) medical propellant.
HFO-1234ze is a fourth-generation refrigerant.
The Morris Plains, New Jersey–based company says the new medical propellant has near-zero global warming potential (GWP) and is suitable for use in respiratory inhalers.
The Solstice Air product is exempt from federal volatile organic compound (VOC) requirements.
Honeywell has announced that its client AstraZeneca (LON:AZN) is working on using Honeywell’s Solstice Air technology as a medical propellant in its triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate).FDA approved Breztri Aerosphere as a maintenance treatment for COPD in 2020.